RVMD vs. UTHR: Revolution Medicines vs. United Therapeutics Stock Comparison

Company Profile

Revolution Medicines (RVMD) and United Therapeutics (UTHR) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

United Therapeutics (UTHR) has more than two decades of public-market history since June 17, 1999, whereas Revolution Medicines (RVMD) listed on February 13, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Revolution Medicines (RVMD) has an aggressive beta of 1.42, indicating higher sensitivity to broad-market moves, while United Therapeutics (UTHR) is defensive at 0.49 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Revolution Medicines (RVMD) reports a negative ROE of -93.56%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile United Therapeutics (UTHR) reports 19.13%, ranking against industry peers normally.

United Therapeutics (UTHR) at 38.61% converts revenue to bottom-line profit above its industry’s benchmark range, while Revolution Medicines (RVMD) at 0.00% keeps roughly the typical share for its industry.

Revolution Medicines (RVMD) reports a negative operating margin of -188.88%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile United Therapeutics (UTHR) reports 28.99%, ranking against industry peers normally.

Profitability Metrics

Growth

Only one side can be read here: United Therapeutics (UTHR) reports revenue growth of 10.61%, ranked against its industry; Revolution Medicines (RVMD) has no revenue growth figure this period.

Only one side can be read here: United Therapeutics (UTHR) reports EPS growth of 13.07%, ranked against its industry; Revolution Medicines (RVMD) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Revolution Medicines (RVMD) at 8.36 and United Therapeutics (UTHR) at 4.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Only one side’s leverage can be read here: Revolution Medicines (RVMD) carries debt-to-equity ratio of 0.50 against its industry range, while United Therapeutics (UTHR) reports no figure this period.

Financial Strength Metrics

Dividends

Neither Revolution Medicines (RVMD) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Revolution Medicines (RVMD) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: United Therapeutics (UTHR) trades at 21.22 times trailing earnings, ranked against its peers, while Revolution Medicines (RVMD) has no P/E ratio this period.

United Therapeutics (UTHR) at 7.51 prices around its industry’s typical P/S ratio, while Revolution Medicines (RVMD) at 210.51 clears its benchmark range — RVMD looks notably rich on sales.

United Therapeutics (UTHR) at 3.80 sits near its industry’s typical P/B ratio, while Revolution Medicines (RVMD) at 17.31 prices above its benchmark range — RVMD looks rich relative to book.

Valuation Metrics